Award

Non-viral gene delivery platforms for the treatment of Usher Syndrome Type 2A.

Description: PROJECT NARRATIVE Mutations in USH2A, which are responsible for ~85% of all USH2 cases, lead to severe auditory defects and late onset retinitis pigmentosa (RP), and in some cases autosomal recessive non-syndromic RP. Developing an effective treatment for USH2A has been challenging due to its very large coding sequence and the presence of isoforms with functions that are not fully understood. We aim to extend the benefits of our proven non-viral gene therapy platform consisting of nanoparticles, nanospheres, and sulfotyrosine to enhance delivery, protection, controlled release, and distribution of intravitreally delivered Ush2a gene to rescue vision loss associated with USH2A.
Funding type: research
Funder scheme: R01
Start date: 2023-01-01
End date: 2026-12-31
Investigator: MUNA I. NAASH (lead)
Subfield: Ophthalmology
Field: Medicine
Funded outputs count: 9
Funder award ID: R01EY034671
OpenAlex ID: G9000880445
2024 · Christian T. Rutan Woods, Mustafa S. Makia, et al. · Nature Communications · 7
2024 · Ryan Crane, Mustafa S. Makia, et al. · Molecular Therapy — Nucleic Acids · 9
2024 · Lars Tebbe, Mashal Kakakhel, et al. · Frontiers in Cellular Neuroscience · 9
2023 · Tylor R. Lewis, Mustafa S. Makia, et al. · eLife · 9
2023 · Tylor R. Lewis, Mustafa S. Makia, et al. · eLife · 1
2023 · Lars Tebbe, Maggie L. Mwoyosvi, et al. · Nature Communications · 19